Juliana Barbosa Saliba

In vitro release and characterization of chitosan films as dexamethasone carrier

Chitosan, a biodegradable and biocompatible polysaccharide, is a potentially useful material in various fields. We produced mono and bilayer chitosan films containing dexamethasone as a drug carrier for controlled release. The chitosan drug-loaded films were produced by a casting/solvent evaporation technique using 2 wt% acetic acid solution and distilled water and they were dried at room temperature. These films were characterized by release and swelling studies, DSC and ATR-FTIR. The total profile for water absorption was similar for the types of films developed. ATR-FTIR analysis showed little change in the band position of the O--H and N--H stretching from dexamethasone and chitosan, respectively. DSC analysis from bilayer film indicates that the dexamethasone peak was shifted from 256 to 240 degrees C. These results suggested an interaction between hydroxyl and amino groups of chitosan and hydroxyl groups of dexamethasone. In the drug release studies it was observed 89.6% release from the monolayer film in 8h and 84% from the bilayer film in 4 weeks. These results suggested that the chitosan sheet prepared in this study is a promising delivery carrier for dexamethasone.

Surface modified fluorescent quantum dots with neurotransmitter ligands for potential targeting of cell signaling applications

The possibility of combining nanotechnology with nanomedicine opens a broad field of research which may truly revolutionize our society. The neural system plays a crucial role in the human body, and most related diseases can dramatically change the quality of life. Thus, the present study reports a novel approach for using neurotransmitters as ligands in the synthesis of surface-modified fluorescent nanocrystals for potential use in cell labeling applications. Briefly, CdS quantum dots (QDs) were prepared using L-glutamic and L-aspartic as surface capping agents via a one-step chemical processing method, which resulted in stable aqueous colloidal systems at room temperature and ambient pressure. UV-visible spectroscopy, photoluminescence spectroscopy (PL), Fourier transform infrared (FTIR) spectroscopy, and transmission electron microscopy (TEM) were used to characterize the synthesis and relative stability of peptide-capped CdS nanocrystals. The results demonstrate that both ligands were effective in nucleating and stabilizing CdS quantum dots in colloidal aqueous suspensions, with an estimated dimension below 3.3 nm and with fluorescence activity. Thus, novel nanohybrids were developed based on QDs bioconjugated to surface-active neurotransmitter moieties suitable for investigation as potential biomarkers in cell targeting and signaling applications.

Development and characterization of an intraocular biodegradable polymer system containing cyclosporine-A for the treatment of posterior uveitis

The aim of this study was to synthesize and characterize the biodegradable intraocular implants based on poly (D,L-lactide-co-glycolide) (PLGA 75:25) with Cyclosporine-A (CyA) and to evaluate their in vitro drug delivery profile. Thermal analysis was conducted by using Thermogravimetry (TG) and Differential Scanning Calorimetry (DSC). Phase analysis and crystallinity of the polymer-CyA samples were assessed through X ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR). Finally, microstructure and morphology of the systems were investigated by Scanning Electron Microscopy (SEM). The results showed that CyA was successfully incorporated into PLGA network with drug loading of approximately 31.6%. Also, based on FTIR and thermal analyses (TGA/DSC) no significant physical-chemical interaction was detected at the micro-nanoscale level between polymer/drug. SEM micrographs have indicated a uniform drug distribution in PLGA matrix. XRD patterns have showed that the incorporated semi-crystalline structure of CyA has not significantly altered the polymeric mainly amorphous network. In addition, the results have confirmed the chemical and biological drug stability, the drug distribution into the polymeric matrix and the possibility of cyclosporine prolonged delivery system profile.

Vitreous Pharmacokinetics and Retinal Safety of Intravitreal Preserved Versus Non-preserved Triamcinolone Acetonide in Rabbit Eyes

Purpose: To compare the intravitreal pharmacokinetic profile of a triamcinolone acetonide formulation containing the preservative benzyl alcohol (TA-BA) versus a preservative-free triamcinolone acetonide formulation (TA-PF), and evaluate potential signs of toxicity to the retina. Methods: A total of 60 New Zealand male white rabbits, divided into two groups, were studied. In the TA-BA group, 30 rabbits received an intravitreal injection of TA-BA (4 mg/0.1ml) into the right eye. In the TA-PF group, 30 rabbits received an intravitreal injection of TA-PF (4 mg/0.1ml) into the right eye. The intravitreal drug levels were determined in 25 animals from each group by high-performance liquid chromatography (HPLC). The potential for toxicity associated with the intravitreal triamcinolone injections was evaluated in five randomly selected animals from each group by electroretinography (ERG) and by light microscopy. Results: Median intravitreal concentrations of TA-BA (µg/ml) were 1903.1, 1213.0, 857.8, 442.0, 248.6 at 3, 7, 14, 21 and 28 days after injection. Intravitreal concentrations of TA-PF (µg/ml) were 1032.9, 570.1, 516.6, 347.9, 102.8 at 3, 7, 14, 21 and 28 days after injection. The median intravitreal triamcinolone concentration was significantly higher in the TA-BA compared to the TA-PF group at 7 days post-injection (p < 0.05). There was no significant difference between the two groups in median triamcinolone concentration at the other time points evaluated. There was no evidence of toxic effects on the retina in either group based on ERG or histological analyses. Conclusions: Following a single intravitreal injection, the median concentration of triamcinolone acetonide is significantly higher in the TA-BA compared to the TA-PF group at 7 days post-injection. No toxic reactions in the retina were observed in either group.

Polyurethanes as supports for human retinal pigment epithelium cell growth

Purpose The transplant of retinal pigment epithelium (RPE) cells on supports may well be an effective therapeutic approach to improve the visual results of patients with age-related macular degeneration. In this study, two biodegradable polyurethanes were investigated as supports for human RPE cells (ARPE-19). Methods Polyurethane aqueous dispersions based on poly(caprolactone) and/or poly(ethylene glycol) as soft segments, and isophorone diisocyanate and hydrazine as hard segments were prepared. Polyurethane films were produced by casting the dispersions and allowing them to dry at room temperature for one week. The ARPE-19 cells were seeded onto the polyurethane films and they were investigated as supports for in vitro adhesion, proliferation, and uniform distribution of differentiated ARPE-19 cells. Additionally, the in vivo ocular biocompatibility of the polyurethane films was evaluated. Results The RPE adhered to and proliferated onto the polyurethane supports, thus establishing cellPUD surface interactions. Upon confluence, the cells formed an organized monolayer, exhibited a polygonal appearance, and displayed actin filaments which ran along the upper cytoplasm. At 15 days of seeding, the occluding expression was confirmed between adjacent cells, representing the barrier functionality of epithelial cells on polymeric surfaces and the establishment of cell-cell interactions. Results from the in vivo study indicated that polyurethanes exhibited a high degree of short-term intraocular biocompatibility. Conclusions Biodegradable polyurethane films display the proper mechanical properties for an easy transscleral-driven subretinal implantation and can be considered as biocompatible supports for a functional ARPE-19 monolayer.

Characterization and in vitro release of cyclosporine-A from poly(D,L-lactide-co-glycolide implants obtained by solvent/extraction evaporation

Cyclosporine-A-loaded PLGA implants were developed intended for ocular route. Implants were prepared using solvent extraction/ evaporation technique followed by casting of the cake into rods in a heated surface. XRD patterns showed that cyclosporine-A was completely incorporated into PLGA. FTIR and DSC results indicated alterations on drug molecular conformation aiming to reach the most stable thermodynamic conformation at polymer/drug interface. Implants provided controlled/sustained in vitro release of the drug. During the first 7 weeks, the drug release was controlled by the diffusion of the cyclosporine-A; and between 7-23 week period, the drug diffusion and degradation of PLGA controlled the drug release.

Development and validation of a high performance liquid chromatographic method for determination of cyclosporine-A from biodegradable intraocular implants

C and UV detection at 210 nm. The method provided selectivity based on resolution among peaks. It was linear over the range of 2.5-40.0 µg/mL. The quantitation and detection limits were 0.8 and 1.2 µg/mL, respectively. The recovery was 101.8% and intra-day and inter-day precision was close to 2%.

Sistema de liberação contendo ciclosporina para o tratamento de ceratoconjuntivite seca: estudo preliminar

Purpose: The present work aimed to present the development of a conjunctival mucosa system for the controlled delivery of cyclosporine A (CsA) in the treatment of keratoconjunctivitis sicca (KCS). Methods: The conjunctival mucosa system was prepared in the form of films containing chitosan as the polymer and CsA as the drug (25%w/v). The films were applied to the conjunctival sac of one eye from normal rabbits (n=6), and the evaluation of lachrymal production was performed daily, before and after application, for seven days. Clinical examination was executed daily on the eyes of each animal during the entire period of study. Histological analyses were carried out at the end of the study. Results: The average amount of lachrymal production changed from 9.88 ± 0.37 mm/min to 16.02 ± 0.38 mm/min, respectively, before and after applying the systems, which indicates an increase of approximately 60%. All rabbits presented hyperemia in the palpebral conjunctiva and tearing. Hyperemia continued for 48h after the application of the systems with spontaneous resolution, and tearing was diagnosed throughout the entire study. No other sign of undesirable reactions could be observed. Moreover, no histological changes could be identified in the bulbar and palpebral conjunctival mucosa. Conclusion: The developed systems proved to be safe and efficient in this pilot study and present a promising future for the treatment of KCS. Other studies are warranted to evaluate the released concentration of CsA as well as the feasibility and toxicity of these systems in a more prolonged treatment.